class="knockout" style="margin-top: 0px;margin-bottom: 1px;font-size: 14px;line-height: 1.2;padding: 5px;padding-left: 20px;padding-right: 20px;font-weight: normal;">THANK YOU FOR SUBSCRIBING
Anthony Rotunno, Lykan's current CEO, will take up the role of Founder & Executive Vice Chairman and will continue to contribute to the development of the Company.
FREMONT, CA: Lykan Bioscience, contract development and manufacturing services organization and provider of the first true end-to-end solution for the manufacture of cell-based therapies have declared the appointment of Patrick Lucy as its President & Chief Executive Officer, effective April 1, 2021. Patrick will take care of the day-to-day leadership of the Company as well as will join Lykan's Board of Directors. Anthony Rotunno, Lykan's current CEO, will take up the role of Founder & Executive Vice Chairman and will continue to contribute to the development of the Company.
"With his 44 years of experience in biopharmaceutical manufacturing, Anthony has consolidated that vast experience in the founding of Lykan Bioscience and has established an outstanding team and cell therapy manufacturing facility of the future," stated Lykan Bioscience Chairman Peter Crowley, "We look forward to Patrick taking on the leadership of Lykan going forward. The Operating team and the Board are both eager to continue to work with Anthony to support the business as he assumes his new role."
"Patrick has made a significant impact since joining Lykan in January and has played a major role in the company's recent strategic decisions; I am confident in his ability to successfully drive the company forward," stated Lykan Bioscience CEO Anthony Rotunno. "We congratulate Patrick on his transition to his new role and look forward to his continued leadership."